Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

被引：9

作者：

Sanchez, A. ^{[1
]}

Brun, L. R. ^{[2
]}

Salerni, H. ^{[3
]}

Costanzo, P. R. ^{[3
]}

Gonzalez, D. ^{[4
]}

Bagur, A. ^{[4
]}

Oliveri, B. ^{[4
,5
]}

Zanchetta, M. B. ^{[6
]}

Farias, V. ^{[6
]}

Maffei, L. ^{[7
]}

Premrou, V. ^{[7
]}

Mansur, J. L. ^{[8
]}

Larroude, M. S. ^{[9
]}

Sarli, M. A. ^{[6
]}

Rey, P. ^{[6
]}

Ulla, M. R. ^{[10
]}

Pavlove, M. M. ^{[11
]}

Karlsbrum, S. ^{[11
]}

Brance, M. L. ^{[12
]}

机构：

[1] Ctr Endocrinol, Rosario, Argentina

[2] Univ Nacl Rosario, Fac Ciencias Med, Lab Biol Osea, Rosario, Argentina

[3] CICEMO, Buenos Aires, DF, Argentina

[4] Mautalen Salud & Invest, Buenos Aires, DF, Argentina

[5] UBA CONICET, La Osteoporosis & Enfermedades Metab Oseas, INIGEM, Hosp Clin, Buenos Aires, DF, Argentina

[6] Univ Salvador, Inst Diagnost & Invest Metab IDIM, Catedra Osteol & Metab Mineral, Buenos Aires, DF, Argentina

[7] Consultorios Asociados Endocrinol Dra Laura Maffe, Buenos Aires, DF, Argentina

[8] Ctr Endocrinol & Osteoporosis, La Plata, Buenos Aires, Argentina

[9] Hosp Milstein, Buenos Aires, DF, Argentina

[10] Ctr Endocrinol & Osteopatias Med, Cordoba, Argentina

[11] Hosp Durand, Buenos Aires, DF, Argentina

[12] Ctr Reumatol, Rosario, Argentina

来源：

JOURNAL OF OSTEOPOROSIS | 2016年 / 2016卷

关键词：

D O I：

10.1155/2016/8738959

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naive patients (BP-naive) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naive and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean +/- SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naive and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naive and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.

引用

页数：6

共 50 条

[1] Dose–response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
T. Nakamura
T. Matsumoto
T. Sugimoto
M. Shiraki
Osteoporosis International, 2012, 23 : 1131 - 1140
[2] The Effect of Denosumab on Bone Turnover Markers (BTM) in Postmenopausal Women With Osteoporosis
Cummings, Steven
Wang, Andrea
San Martin, Javier
McClung, Mike
Claus, Christiansen
Libanati, Cesar
Siris, Ethel
Eastell, Richard
BONE, 2010, 46 : S28 - S28
[3] Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
Nakamura, T.
Matsumoto, T.
Sugimoto, T.
Shiraki, M.
OSTEOPOROSIS INTERNATIONAL, 2012, 23 (03) : 1131 - 1140
[4] Effects of denosumab on bone mineral density and bone turnover in postmenopausal women
Bone, Henry G.
Bolognese, Michael A.
Yuen, Chui Kin
Kendler, David L.
Wang, Huei
Liu, Yu
Martin, Javier San
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (06): : 2149 - 2157
[5] Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
Wensel, Terri M.
Iranikhah, Maryam M.
Wilborn, Teresa W.
PHARMACOTHERAPY, 2011, 31 (05): : 510 - 523
[6] Effect of Denosumab on bone mineral density and markers of bone turnover
Sanchez, A.
Brun, L. R.
Salerni, H.
Costanzo, P.
Zanchetta, M. B.
Farias, V.
Maffei, L.
Premrou, V.
Larroude, M. S.
Sarli, M. A.
Rey, P.
Brance, M. L.
Pavlove, M. M.
Karlsbrum, S.
BONE, 2016, 89 : 66 - 67
[7] ASSESSMENT OF BONE MINERAL DENSITY AND BONE TURNOVER MARKERS IN POSTMENOPAUSAL WOMEN TRANSITIONED FROM ALENDRONATE TO DENOSUMAB
Roux, C.
Brown, J. P.
Kendler, D. L.
Lillestol, M.
Siddhanti, S.
Man, H. S.
Martin, J. San
Bone, H. G.
Benhamou, C. L.
OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 10 - 11
[8] Effects of raloxifene and alendronate on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis
Johnell, O
Lu, Y
Seeman, E
Reginster, J
Scheele, W
OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S184 - S184
[9] RELATIONSHIP BETWEEN REDUCTION IN BONE TURNOVER MARKERS (BTM) AND CHANGE IN BONE MINERAL DENSITY (BMD) IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS TREATED WITH DENOSUMAB
Eastell, R.
Christiansen, C.
Grauer, A.
Kutilek, S.
Libanati, C.
McClung, M.
Resch, H.
Siris, E.
Uebelhart, D.
Reid, I.
Wang, A.
Weryha, G.
Cummings, S.
OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 185 - 186
[10] The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis
Makras, Polyzois
Papapoulos, Socrates E.
Polyzos, Stergios A.
Appelman-Dijkstra, Natasha M.
Anastasilakis, Athanasios D.
BONE, 2020, 138

← 1 2 3 4 5 →